A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases
Latest Information Update: 16 Mar 2026
At a glance
- Drugs AFN 50 (Primary)
- Indications Autoimmune disorders; Diffuse scleroderma; Myasthenia gravis; Myositis; Sjogren's syndrome; Systemic lupus erythematosus; Vasculitis
- Focus Adverse reactions
Most Recent Events
- 11 Mar 2026 Status changed from not yet recruiting to recruiting.
- 09 Mar 2026 New trial record